The COPD Foundation is partnering with Savana, a machine learning and artificial intelligence company, to develop a way of better identifying people with chronic obstructive pulmonary disease (COPD) who have not yet been diagnosed, or are at high risk of this disease. De-identified data in electronic medical…
Dental care in Brazil needs to be more accessible to patients with chronic obstructive pulmonary disease (COPD) and integrated into their primary care to better tackle the impact of the disease in the country, a study suggests. “Our research indicates that incorporating preventative oral health into COPD management and…
Treatment with PRP-PC, an investigational platelet-based cellular therapy, may slow the decline in lung function typically experienced by people with chronic obstructive pulmonary disease (COPD), a new study with real-world data indicates. With this therapy, being developed by H-CYTE, a person’s own blood is treated in the lab…
Patients with chronic obstructive pulmonary disease (COPD) who engage in activities that put them at risk of being exposed to mold are more likely to experience disease flare-ups, a small U.K. study has found. This may be related to Aspergillus, a type of fungus that grows in damp or…
NuvoAir announced it has raised $12 million in Series A funding, which it will use to expand a digital care platform for people in the U.S. and Europe with serious respiratory disorders like chronic obstructive pulmonary disease (COPD), and to advance work on new products. The company’s NuvoAir Home…
Preventing a specific type of cell death, called necroptosis, may provide a new way of treating chronic obstructive pulmonary disease (COPD), according to data from a recent study. Patients with COPD have elevated levels of necroptosis, the study revealed. Stopping that type of cell death leads to significant reductions…
Teva Pharmaceuticals has launched the first generic version of Perforomist (formoterol fumarate inhalation solution) for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S. “Teva is pleased to provide patients with first-to-market access to a generic version of Perforomist,” Christine Baeder, senior vice president and…
Hospitalizations for chronic obstructive pulmonary disease (COPD) dropped by half after the implementation of public health measures to curb the spread of COVID-19 infections, according to a U.S. study. This reduction in COPD hospital admissions was 36% greater than “the declines seen in other serious medical conditions, including…
Glenmark Pharmaceuticals has launched Tiogiva, a tiotropium bromide dry powder inhaler (DPI) for the treatment of chronic obstructive pulmonary disease (COPD), in the U.K. Tiogiva is the bioequivalent generic version of Boehringer Ingelheim’s…
Although lung cancer development is unpredictable, patients with chronic obstructive pulmonary disease (COPD) appear more likely to have the cancer and a worse prognosis compared with the general population, a Japanese study has found. Annual computed tomography (CT) screens may help with the early detection and treatment of this…
Get regular updates to your inbox.